A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Rezolute, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,000 shares of RZLT stock, worth $5,800. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,000
Previous 398,423 99.75%
Holding current value
$5,800
Previous $1.02 Million 99.61%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.29 - $5.79 $139,435 - $352,547
-60,889 Reduced 15.28%
337,534 $1.45 Million
Q1 2024

May 15, 2024

BUY
$0.95 - $2.55 $49,280 - $132,278
51,874 Added 14.97%
398,423 $1.02 Million
Q4 2023

Feb 14, 2024

BUY
$0.74 - $1.24 $22,410 - $37,553
30,285 Added 9.58%
346,549 $343,000
Q3 2023

Nov 14, 2023

SELL
$1.32 - $2.1 $15,277 - $24,305
-11,574 Reduced 3.53%
316,264 $417,000
Q2 2023

Aug 14, 2023

SELL
$1.75 - $2.33 $22,748 - $30,287
-12,999 Reduced 3.81%
327,838 $649,000
Q1 2023

May 15, 2023

SELL
$1.79 - $2.87 $22,729 - $36,443
-12,698 Reduced 3.59%
340,837 $654,000
Q4 2022

Feb 14, 2023

BUY
$1.38 - $2.84 $56,793 - $116,880
41,155 Added 13.17%
353,535 $731,000
Q3 2022

Nov 14, 2022

BUY
$2.19 - $3.49 $9,749 - $15,537
4,452 Added 1.45%
312,380 $856,000
Q2 2022

Aug 15, 2022

SELL
$2.6 - $3.85 $52,065 - $77,096
-20,025 Reduced 6.11%
307,928 $995,000
Q1 2022

May 16, 2022

BUY
$2.27 - $5.1 $44,641 - $100,296
19,666 Added 6.38%
327,953 $1.11 Million
Q4 2021

Feb 14, 2022

SELL
$4.21 - $7.61 $7,152 - $12,929
-1,699 Reduced 0.55%
308,287 $0
Q3 2021

Nov 15, 2021

BUY
$7.45 - $13.66 $14,885 - $27,292
1,998 Added 0.65%
309,986 $2.3 Million
Q2 2021

Aug 16, 2021

SELL
$6.11 - $15.99 $26,566 - $69,524
-4,348 Reduced 1.39%
307,988 $0
Q1 2021

May 17, 2021

BUY
$6.83 - $17.3 $55,357 - $140,216
8,105 Added 2.66%
312,336 $2.21 Million
Q4 2020

Feb 16, 2021

BUY
$11.99 - $24.05 $3.65 Million - $7.32 Million
304,231 New
304,231 $3.76 Million

Others Institutions Holding RZLT

About Rezolute, Inc.


  • Ticker RZLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,600
  • Market Cap $225M
  • Description
  • Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...
More about RZLT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.